Filgotinib (Jyseleca®). HTA ID: 21048

Assessment Status Assessment process complete
HTA ID 21048
Drug Filgotinib
Brand Jyseleca®
Indication For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.
Assessment Process
Rapid review commissioned 01/11/2021
Rapid review completed 10/12/2021
Rapid review outcome A full HTA is not recommended. The NCPE recommends that filgotinib not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations May 2022.